Tryptophan Hydroxylase 1 (TPH1) Recombinant Rabbit monoclonal Antibody IgG
Fig1: Immunohistochemical analysis of paraffin-embedded rat brain tissue using anti-TPH1 antibody. Counter stained with hematoxylin.
Fig2: Immunohistochemical analysis of paraffin-embedded mouse cerebellum tissue using anti-TPH1 antibody. Counter stained with hematoxylin.
Fig3: Flow cytometric analysis of Hela cells with TPH1 antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti rabbit IgG was used as the secondary antibody.
Host Species; Species ReactivityRabbit; Human, Mouse, Rat
Application SummaryWB, ICC/IF, IHC, IP, FC
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesTryptophan 5-hydroxylase 1, Tryptophan 5-monooxygenase 1
BackgroundPhenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH) comprise a small family of monooxygenases that use tetrahydropterine as a cofactor during the catabolism of aromatic L-amino acids. PAH, TH and TPH all contain catalytic domains with an amino-terminal regulatory domain and a short carboxy-terminal tetramerization domain. Each of these enzymes also contains a single ferrous iron atom, which is bound to two histidines and a glutamate and is likely to be involved in the formation of the hydroxylating intermediate. TPH is the first and rate-limiting step in the biosynthesis of serotonin in the central nervous system and melatonin in the pineal gland. Alteration of TPH function may be a key factor in the pathology of several neuropsychiatric disorders associated with serotonin, including depression, aggression, alcoholism and schizophrenia. For instance, L-DOPA, which is used as a common therapy for Parkinson’s disease (PD) patients, inhibits TPH function, which subsequently, is thought to contribute to the onset of depression in PD patients.(ET1610-37)